Tradestie Institutional Equity Comparison Engine
SRZN vs RADX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
SRZN Overall Edge
SRZN Captures Institutional Edge (3โ0 Pillars ยท 5โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Surrozen, Inc. Common (SRZN) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, SRZN trades at N/M Forward P/E with -485.4% operating margin (+408.6% YoY revenue) versus RADX at N/M Forward P/E and -411.6% operating margin (-36.9% YoY). In options structure, SRZN sits in CONSOLIDATION (13th %ile IV; Dealer Gamma Walls on Pro) against RADX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
SRZN N/M vs RADX N/M Fwd P/E
Growth & Margin Winner
SRZN
Op Margin -485.4% vs -411.6% ยท YoY +408.6% vs -36.9%
Momentum & Technical Winner
SRZN
1Y +110.8% vs -86.0% ยท 52W Pos 63% vs 0%
Options & Structure Winner
SRZN
CONSOLIDATION (13th %ile IV) vs UNCLASSIFIED (N/A IV)
SRZN
NASDAQ
Surrozen, Inc. Common
Biological Products, (No Disgnostic Substances)
$28.46
-7.21% 1D
Market Cap
$642.7M
1M Return
+10.52%
1Y Return
+110.81%
Forward P/E
N/M
Unified AI Score
36.0 / 100
SELL
Tech 15.0
Fund 42.0
Flow 65.0
Mom 50.0
RADX
NASDAQ
Radiopharm Theranostics Limited American Depositary Shares
Pharmaceutical Preparations
$0.63
-6.33% 1D
Market Cap
$10.6M
1M Return
-33.64%
1Y Return
-86.04%
Forward P/E
N/M
Unified AI Score
41.1 / 100
SELL
Tech 25.0
Fund 45.0
Flow 50.0
Mom 55.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
SRZN +110.81%
RADX -86.04%
Spread: +197.16 pp (SRZN Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
SRZN TTM Op. Margin: -485.4%
RADX TTM Op. Margin: -411.6%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SRZN vs RADX. Trailing 12-month operating profitability (SRZN -485.4% vs RADX -411.6%) and valuation multiples (SRZN N/M vs RADX N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | SRZN | RADX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $642.7M | $10.6M | Larger Scale | SRZN |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +408.6% | -36.9% | Higher Growth | SRZN |
| Operating Margin (TTM) Profitability | -485.4% | -411.6% | Higher Margin | RADX |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -62.8% | -174.7% | Higher ROE | SRZN |
| 52-Week Range Position Momentum | 63% ($13โ$38) | 0% ($1โ$16) | Stronger Trend | SRZN |
| Beta / 30D Volatility Risk Regime | 1.29ฮฒ ยท 73% Vol | 0.52ฮฒ ยท 109% Vol | Lower Realized Risk | SRZN |
| Unified Institutional Score Composite Signal | 36.0 / 100 (SELL) | 41.1 / 100 (SELL) | Higher Composite | RADX |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full SRZN vs RADX Buy Guide
SRZN
CONSOLIDATION
41d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
13th %ile
IV Regime
Compressed (<25th %ile)
RADX
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither SRZN nor RADX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.